nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-587Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЖелезо (III) гидроксид олигоизомальтозат: новый препарат для коррекции дефицита железа у больных ХБП (Обзор литературы)Iron (III) hydroxide olygoisomaltozat: a new drug for the correction of iron deficiency in patients with CKD ReviewЕрмоленкоВ. М.ErmolenkoV. M.nephrology@mail.ruФилатоваН. Н.FilatovaN. N.noemail@neicon.ruГБОУ ДПО РМАПО Министерства здравоохранения РФ, г. МоскваРоссияRussian medical Academy for post-graduate education, MoscowRussian Federation201320092024152120123Copyright © Ермоленко В.М., Филатова Н.Н., 20242024Ермоленко В.М., Филатова Н.Н.Ermolenko V.M., Filatova N.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/587

В обзоре рассматриваются дискуссионные вопросы коррекции анемии у больных ХБП с нарушением функции почек. Особое внимание уделено препаратам железа, в частности, новому препарату – железо (III) гидроксид олигоизомальтозат 1000, который уже зарегистрирован в России. Линейная структура и сравнительно небольшая молекулярная масса минимизируют влияние препарата на иммунную систему, а матриксное расположение молекул железа обеспечивает его медленное высвобождение и крайне незначительное присутствие в сыворотке свободного железа, способного вызывать токсические эффекты. Железо (III) гидроксид олигоизомальтозат в дозе ³1000 мг можно вводить внутривенно в течение 15 мин без предварительной инфузии тестовой дозы.

The review discusses the correction of anemia in CKD patients with impaired renal function. Special attention is given to iron supplements, especially new drug iron (III) hydroxide olygoisomaltozat which has already been registered in Russia. Linear structure and relatively small molecular weight minimized the impact of the drug on the immune system. Matrix disposition of iron's molecules provides its slow release and very little presence of free iron in the serum, which might cause toxic effects. Iron (III) hydroxide olygoisomaltozat dose of ³1000 mg may be administered intravenously over 15 minutes without pre-infusion test dose.

chronic kidney diseaseanemiairon drugsepoetiniron (III) hydroxide olygoisomaltozatchronic kidney diseaseanemiairon drugsepoetiniron (III) hydroxide olygoisomaltozatReferencesBesarab A., Bolton W., Browne J. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin // N. Engl. J. Med. 1998. Vol. 339. P. 584–590.Besarab A., Bolton W., Browne J. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin // N. Engl. J. Med. 1998. Vol. 339. P. 584–590.Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000 // Ther. Clin. Risk Manag. 2011. Vol. 7. P. 103–113.Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000 // Ther. Clin. Risk Manag. 2011. Vol. 7. P. 103–113.Coyne D. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy // Semin. Dial. 2008. Vol. 21. P. 212–216.Coyne D. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy // Semin. Dial. 2008. Vol. 21. P. 212–216.Coyne D. The future of intravenous iron in nephrology // NDT Plus. 2011. Vol. 4. P. i6–i9.Coyne D. The future of intravenous iron in nephrology // NDT Plus. 2011. Vol. 4. P. i6–i9.Drüeke T., Locatelli F., Clyne N. et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia // N. Engl. J. Med. 2006. Vol. 355. P. 2071–2084.Drüeke T., Locatelli F., Clyne N. et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia // N. Engl. J. Med. 2006. Vol. 355. P. 2071–2084.Ford B., Coyne D., Eby C. et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management // Kidney Int. 2009. Vol. 75. 104–110.Ford B., Coyne D., Eby C. et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management // Kidney Int. 2009. Vol. 75. 104–110.Gotloib L., Silverberg D., Fudin R., Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron // J. Nephrol. 2006. Vol. 19. P. 161–167.Gotloib L., Silverberg D., Fudin R., Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron // J. Nephrol. 2006. Vol. 19. P. 161–167.Hildebrant P., Brunn N., Nielsen O. et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfusion Alternatives in Transfusion Medicine // 2010. Vol. 11. P. 131–137.Hildebrant P., Brunn N., Nielsen O. et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfusion Alternatives in Transfusion Medicine // 2010. Vol. 11. P. 131–137.Jahn M., Andreasen H., Fütterer S. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications // Eur. J. Pharm. Biopharm. 2011. Vol. 78. P. 480–491.Jahn M., Andreasen H., Fütterer S. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications // Eur. J. Pharm. Biopharm. 2011. Vol. 78. P. 480–491.KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target // Am. J. Kidney Diseases. 2007. Vol. 50. P. 471–530.KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target // Am. J. Kidney Diseases. 2007. Vol. 50. P. 471–530.Landry R., Jacobs P., Davis R. et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients // Am. J. Nephrol. 2005. Vol. 25. P. 400–410.Landry R., Jacobs P., Davis R. et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients // Am. J. Nephrol. 2005. Vol. 25. P. 400–410.Leyland-Jones B, Semiglazov V, Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study // J. Clin. Oncol. 2005. Vol. 23. P. 5960–5972.Leyland-Jones B, Semiglazov V, Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study // J. Clin. Oncol. 2005. Vol. 23. P. 5960–5972.Locatelli F. Iron treatment and the TREAT trial // NDT Plus. 2011. Vol. 4. P. i3–i5.Locatelli F. Iron treatment and the TREAT trial // NDT Plus. 2011. Vol. 4. P. i3–i5.Locatelli F., Aljama P., Barany P. et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure // NDT. 2004. Vol. 19. P. 1–47.Locatelli F., Aljama P., Barany P. et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure // NDT. 2004. Vol. 19. P. 1–47.Macdougall I., Eckardt K., Locatelli F. Latest US KDOQI anaemia guidelines update-what are the implications for Europe? // NDT. 2007. Vol. 22. P. 2738–2742.Macdougall I., Eckardt K., Locatelli F. Latest US KDOQI anaemia guidelines update-what are the implications for Europe? // NDT. 2007. Vol. 22. P. 2738–2742.Macdougall I., Temple R., Kwan J. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial // NDT. 2007. Vol. 22. P. 784–793.Macdougall I., Temple R., Kwan J. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial // NDT. 2007. Vol. 22. P. 784–793.Nordfjeld K., Andreasen H., Thomsen L. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease // Drug. Des. Devel. Ther. 2012. Vol. 6. P. 43–51.Nordfjeld K., Andreasen H., Thomsen L. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease // Drug. Des. Devel. Ther. 2012. Vol. 6. P. 43–51.Pai A., Nielsen J.C., Kausz A. et al. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects // Clin. Pharmacol. Ther. 2010. Vol. 88. P. 237–242.Pai A., Nielsen J.C., Kausz A. et al. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects // Clin. Pharmacol. Ther. 2010. Vol. 88. P. 237–242.Parfrey P., Foley R., Wittreich B. et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2180–2189.Parfrey P., Foley R., Wittreich B. et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2180–2189.Pfeffer M., Burdmann E., Chen C. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease // N. Engl. J. Med. 2009. Vol. 361. P. 2019–2032.Pfeffer M., Burdmann E., Chen C. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease // N. Engl. J. Med. 2009. Vol. 361. P. 2019–2032.Provenzano R., Schiller B., Rao M. et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. P. 386–393.Provenzano R., Schiller B., Rao M. et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. P. 386–393.Singh A. Does TREAT give the boot to ESAs in the treatment of CKD anemia? // J. Am. Soc. Nephrol. 2010. Vol. 28. P. 1–4.Singh A. Does TREAT give the boot to ESAs in the treatment of CKD anemia? // J. Am. Soc. Nephrol. 2010. Vol. 28. P. 1–4.Singh A., Szczech L., Tang K. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease // N. Engl. J. Med. 2006. Vol. 355. P. 2085–2098.Singh A., Szczech L., Tang K. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease // N. Engl. J. Med. 2006. Vol. 355. P. 2085–2098.Solomon S., Uno H., Lewis E. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes // N. Engl. J. Med. 2010. Vol. 363. P. 1146–1155.Solomon S., Uno H., Lewis E. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes // N. Engl. J. Med. 2010. Vol. 363. P. 1146–1155.Spinowitz S., Kausz A., Baptista J. et al. Ferumoxytol for treating iron deficiency anemia in CKD // J. Am. Soc. Nephrol. 2008. Vol. 19. P. 1599–1605.Spinowitz S., Kausz A., Baptista J. et al. Ferumoxytol for treating iron deficiency anemia in CKD // J. Am. Soc. Nephrol. 2008. Vol. 19. P. 1599–1605.Stancu S., Bârsan L., Stanciu A. et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? // Clin. J. Am. Soc. Nephrol. 2010. Vol. 5. P. 409–416.Stancu S., Bârsan L., Stanciu A. et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? // Clin. J. Am. Soc. Nephrol. 2010. Vol. 5. P. 409–416.Strippoli G., Tognoni G., Navaneethan S. et al. Haemoglobin targets: we were wrong, time to move on // Lancet. 2007. Vol. 369. P. 346–350.Strippoli G., Tognoni G., Navaneethan S. et al. Haemoglobin targets: we were wrong, time to move on // Lancet. 2007. Vol. 369. P. 346–350.Szczech L., Barnhart H., Inrig J. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes // Kidney Int. 2008. Vol. 74. P. 791–798.Szczech L., Barnhart H., Inrig J. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes // Kidney Int. 2008. Vol. 74. P. 791–798.Warady B., Seligman P., Dahl N. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2. P. 1140–1146.Warady B., Seligman P., Dahl N. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2. P. 1140–1146.Wikström B., Bhandari S., Barany P. et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease // J. Nephrol. 2011. Vol. 24. P. 589–596.Wikström B., Bhandari S., Barany P. et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease // J. Nephrol. 2011. Vol. 24. P. 589–596.

The authors declare that there are no conflicts of interest present.